Online inquiry

IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10682MR)

This product GTTS-WQ10682MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFSF13B gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001145645.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10673
UniProt ID Q9Y275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ10682MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1730MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ADC-1013
GTTS-WQ13963MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ1766MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ5080MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CAM-3001
GTTS-WQ3863MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BCD-089
GTTS-WQ13785MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-1033
GTTS-WQ13532MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRX-003
GTTS-WQ11915MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MLN2045
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW